What's new

Orphan designation: volixibat potassium Treatment of primary biliary cholangitis, 16/01/2025 Positive

Orphan designation: volixibat potassium Treatment of primary biliary cholangitis, 16/01/2025 Positive

Feb 20, 2025 - 15:02
 0
Orphan designation: volixibat potassium Treatment of primary biliary cholangitis, 16/01/2025 Positive
Orphan designation: volixibat potassium Treatment of primary biliary cholangitis, 16/01/2025 Positive
Read More

Tags:

Previous Article

Genentech, Novartis join forces to raise awareness of food allergies’ impact on ...

Next Article

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, D...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Uplizna, Inebilizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Immune system disorders, PIP number: P/0531/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 13, 2025  0

Investigation of bioequivalence - Scientific guideline

Investigation of bioequivalence - Scientific guideline

Feb 26, 2025  0

Guideline on assessment and reporting of mechanistic models used in the context of model informed drug development

Guideline on assessment and reporting of mechanistic mo...

Feb 14, 2025  0